top of page
ROI_001_BlueSMA_RedPan-CK_YellowCD8a_LimeCD45RO_Gauss_blur_3.tif

Publications

Selected publications

Müller N, Lorenz C, Ostendorp J, Heisel F, Friese U, Cartolano M, Plenker D, Tumbrink HL, Heimsoeth A, Baedeker P, Weiss J, Ortiz-Cuaran S, Büttner R, Peifer M, Thomas RK, Sos ML, Berg J, Brägelmann J.

Characterizing evolutionary dynamics reveals strategies to exhaust the spectrum of subclonal resistance in EGFR-mutant lung cancer.

Cancer Research 2023

Malchers F, Nogova L, van Attekum M, Maas L, Brägelmann J, Bartenhagen C, Girard L, Bosco G, Dahmen I, Michels S, Weeden CE, Scheel AH, Meder L, Golfmann K, Schuldt P, Siemanowski J, Rehker J, Merkelbach-Bruse S, Gautschi O, Heuckmann J, Brambilla E, Asselin-Labat ML, Persigehl T, Minna J, Walczak H, Ullrich RT, Fischer M, Reinhardt HC, Wolf J, Büttner R, Peifer M, George J, Thomas RK.

Somatic ectodomain deletions of FGFR1 in squamous cell lung cancer.

Journal of Clinical Investigations 2023

Arolt C, Dugan M, Wild R, Richartz V, Holz B, Scheel AH, Brägelmann J, Wagener-Ryczek S, Merkelbach-Bruse S, Wolf J, Buettner R, Catanzariti L, Scheffler M, Hillmer AM.

KEAP1/NFE2L2 pathway signature outperforms KEAP1/NFE2L2 mutation status and reveals alternative pathway-activating mutations in Non-Small Cell Lung Cancer.

Journal of Thoracic Oncology 2023

Glaser M, Rasokat A, Prang D, Nogova L, Wömpner C, Schmitz J, Bitter E, Terjung I, Eisert A, Fischer R, John F, Von Levetzow C, Michels S, Riedel R, Ruge L, Scharpenseel H, Siebolts U, Merkelbach-Bruse S, Buettner R, Brägelmann J, Wolf J, Scheffler M.

Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.

Lung Cancer 2023

2023

Borchmann S, Selenz C, Lohmann M, Ludwig H, Gassa A, Brägelmann J, Lohneis P, Meder L, Mattlener J, Breid S, Nill M, Fassunke J, Wisdom A, Compes A, Gathof B, Alakus H, Kirsch D, Hekmat K, Büttner R, Reinhardt HC, Hallek M, Ullrich RT.

Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors

Journal for Immunotherapy of Cancer 2022

Müller F, Lim JKM, Bebber CM, Seidel E, Tishina S, Dahlhaus A, Stroh J, Beck J, Yapici FI, Nakayama K, Torres Fernández L, Brägelmann J, Leprivier G, von Karstedt S.

Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation.

Cell Death & Differentiation 2022

Selenz C, Compes A, Nill M, Borchmann S, Odenthal M, Florin A, Brägelmann J, Büttner R, Meder L, Ullrich RT.

EGFR inhibition strongly modulates the tumour immune microenvironment in EGFR-driven non-small cell lung cancer.

Cancers 2022

Lategahn J, Tumbrink H, Schultz-Fademrecht C Heimsoeth A, Werr L, Niggenaber J, Keul M, Parmaksiz F, Baumann M, Menninger S, Zent E, Landel I, Weisner J, Jeyakumar K, Heyden L, Russ N, Müller F Lorenz C, Brägelmann J, Spille I, Grabe T, Müller M, Heuckmann J, Klebl B, Nussbaumer P, Sos ML, Rauh D.

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild-Type-Sparing Inhibitors.

Journal of Medicinal Chemistry 2022

2022

Schaufler D", Ast D",Tumbrink H, Abedpour N, Maas L, Schwäbe A, Spille I, Lennartz S, Fassunke J, Aldea M, Besse B, Planchard D, Nogova L, Michels S, Kobe C, Persigehl T, Westphal T, Koleczko S, Fischer R, Weber J, Altmüller J, Thomas R, Merkelbach-Bruse S, Gautschi O, Mezquita L, Büttner R, Wolf J, Peifer M, Brägelmann J*, Scheffler M*, Sos M*.

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.

npj Precision Oncology

(*co-corresponding authors, "contributed equally)

Brägelmann J*", Lorenz C", Borchmann S, Nishii K, Wegner J, Meder L, Ostendorp J, Ast D, Heimsoeth A, Nakasuka T, Hirabae A, Okawa S, Dammert M, Plenker D, Klein S, Lohneis P, Gu J, Godfrey L, Forster J, Trajkovic-Arsic M, Zillinger T, Haarmann M, Quaas A, Lennartz S, Schmiel M, D’Rozario J, Thomas E, Li H, Schmitt CA, George J, Thomas RK, von Karstedt S, Hartmann G, Büttner R, Ullrich RT, Siveke JT, Ohashi K, Schlee M, Sos M*.

MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I.

Nature Communications

(*co-corresponding authors, "contributed equally)

Brägelmann J, Barahona Ponce C, Marcelain K, Roessler S, Goeppert B, Gallegos I, Colombo A, Sanhueza V, Morales E, Rivera MT, de Toro G, Ortega A, Müller B, Gabler F, Scherer D, Waldenberger M, Reischl E, Boekstegers F, Garate Calderon V, Umu SU, Rounge TB, Popanda O, Lorenzo Bermejo J.

Epigenome‐wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer.

Hepatology 2020

Watermann C, Pasternack H, Idel C, Ribbat-Idel J, Brägelmann J, Kuppler P, Offermann A, Jonigk D, Kühnel M, Schröck A, Dreyer E, Rosero C, Nathansen N, Dubrovska A, Tharun L, Kirfel J, Wollenberg B, Perner S, Krupar R.

Comparative immune microenvironment analyses of primary and recurrent HNSCC reveal immunosuppression in recurrences suggesting successful tumor immune evasion.

Clinical Cancer Research 2021

2021

Paulsen F, Idel C, Ribbat-Idel J, Kuppler P, Klapper L, Rades D, Bruchhage K, Wollenberg B, Brägelmann J, Perner S, Offermann A.

CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC

IJMS 2020

Becker F, Joerg V, Hupe MC, Roth D, Krupar R, Lubczyk V, Kuefer R, Sailer V, Duensing S, Kirfel J, Merseburger AS, Brägelmann J, Perner S, Offermann A.

Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer

International Journal of Cancer 2020

2020

Dammert MA*, Brägelmann J*, Olsen RR*, Böhm S*, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretic L, Castiglione R, Lorenz C, Jachimowicz RD, Wolf E, Thomas RK, Poirier JT, Büttner R, Sen T, Byers LA, Reinhardt HC, Letai A, Oliver TG, Sos ML.

MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer

Nature Communications 2020

(*contributed equally)

Scheffler M, Ihle MA, Hein R, Merkelbach-Bruse S, Schee Al, Siemanowski J, Brägelmann J, Kron A, Abedpour N, Ueckeroth F, Schüller M, Koleczko S, Michels S, Fassunke J, Pasternack H, Heydt C, Serke M, Fischer R, Schulte W, Gerigk U, Nogova L, Ko YD, Abdulla DSY, Riedel R, Kambartel K, Lorenz J, Sauerland I, Randerath W, Kaminsky B, Hagmeyer L, Grohé C, Eisert A, Frank R, Gogl L, Schaepers C, Holzem A, Hellmich M, Thomas RK, Peifer M, Sos ML, Büttner R, Wolf J.

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Journal of Thoracic Oncology 2019

Michels S, Heydt C, van Veggel B, Deschler-Baier B, Pardo N, Monkhorst K, Rüsseler V, Stratmann J, Griesinger F, Steinhauser S, Kostenko A, Diebold J, Fassunke J, Fischer R, Engel-Riedel W, Gautschi O, Geissinger E, Haneder S, Ihle MA, Kopp HG, de Langen AJ, Martinez-Marti A, Nogova L, Persigehl T, Plenker D, Puesken M, Rodermann E, Rosenwald A, Scheel AH, Scheffler M, Spengler W, Seggewiss-Bernhardt R, Brägelmann J, Sebastian M, Vrugt B, Hellmich M, Sos ML, Heukamp LC, Felip E, Merkelbach-Bruse S, Smit EF, Büttner R, Wolf J.

Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer

JCO Precision Oncology 2019

2019

2018

Brägelmann J*, Dammert MA*, Dietlein F*, Heuckmann JM*, Choidas A*, Böhm S, Richters S, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, Koch U, Getlik M, Termathe M, Sallouh M, Greff Z, Varga Z, Balke-Want H, French CA, Peifer M, Reinhardt HC, Őrfi L, Kéri G, Ansén S, Heukamp L, Büttner R, Rauh D, Klebl B, Thomas RK, Sos ML.

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma

Cell Reports 2017

Mollaoglu G*, Guthrie MR*, Böhm S*, Brägelmann J*, Can I, Ballieu PM, Marx A, George J, Heinen C, Chalishazar MD, Cheng H, Ireland AS, Denning KE, Mukhopadhyay A, Vahrenkamp JM, Berrett KC, Mosbruger TL, Wang J, Kohan JL, Salama ME, Witt BL, Peifer M, Thomas RK, Gertz J, Johnson JE, Gazdar AF, Wechsler-Reya RJ, Sos ML, Oliver TG.

MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition

Cancer Cell 2017

(*contributed equally)

Brägelmann J, Klümper N, Offermann A, von Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I, Merseburger AS, Vogel W, Sievers E, Vlasic I, Carlsson J, Andrén O, Brossart P, Duensing S, Svensson MA, Shaikhibrahim Z, Kirfel J, Perner S.

Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer

Clinical Cancer Research 2017

2017

bottom of page